Beacon Pointe Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$293K Hold
11,100
﹤0.01% 1548
2025
Q4
$322K Hold
11,100
﹤0.01% 1232
2025
Q3
$308K Buy
+11,100
New +$280K ﹤0.01% 1175

Other funds holding ARKG

Beacon Pointe Advisors's ARKG Position: Q1 2026 in Review

Beacon Pointe Advisors increased its ARK Genomic Revolution ETF (ARKG) stake by 2% in Q1 2026, buying an estimated $72.7K and bringing the position to 126,482 shares worth $3.34M. The position accounts for 0.02% of the portfolio, ranked #591.

Beacon Pointe Advisors first reported a position in ARKG in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.59M in Q4 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Beacon Pointe Advisors held 126,482 shares of ARK Genomic Revolution ETF worth $3.34M as of Q1 2026.
  • Beacon Pointe Advisors bought 2,483 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $72.7K.
  • ARK Genomic Revolution ETF made up 0.02% of Beacon Pointe Advisors's portfolio in Q1 2026, its #591 holding.
  • Beacon Pointe Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2025 and has held it in 5 quarters since.
  • Beacon Pointe Advisors's ARK Genomic Revolution ETF position peaked at $3.59M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.